217 related articles for article (PubMed ID: 1823048)
21. Histologic grade, DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma. A direct comparison.
Humphrey PA; Walther PJ; Currin SM; Vollmer RT
Am J Surg Pathol; 1991 Dec; 15(12):1165-70. PubMed ID: 1746683
[TBL] [Abstract][Full Text] [Related]
22. DNA ploidy and proliferation heterogeneity in human prostate cancers.
Shankey TV; Jin JK; Dougherty S; Flanigan RC; Graham S; Pyle JM
Cytometry; 1995 Sep; 21(1):30-9. PubMed ID: 8529468
[TBL] [Abstract][Full Text] [Related]
23. DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma--necessitating multiple site analysis.
Warzynski MJ; Soechtig CE; Maatman TJ; Goldsmith LC; Grobbel MA; Carothers GG; Shockley KF
Prostate; 1995 Dec; 27(6):329-35. PubMed ID: 7501545
[TBL] [Abstract][Full Text] [Related]
24. Significance of abnormal diploid DNA histograms in localized prostate cancer and adjacent benign prostatic tissue.
Deitch AD; Miller GJ; deVere White RW
Cancer; 1993 Sep; 72(5):1692-700. PubMed ID: 7688657
[TBL] [Abstract][Full Text] [Related]
25. Flow cytometric DNA analysis of advanced prostatic adenocarcinoma.
Wu WJ; Huang MS; Wang HJ; Chiang PH; Huang CH; Chiang CP
Gaoxiong Yi Xue Ke Xue Za Zhi; 1993 Mar; 9(3):122-30. PubMed ID: 8510195
[TBL] [Abstract][Full Text] [Related]
26. Prognostic importance of nuclear DNA content measured by flow cytometry for patients with adenocarcinoma of the prostate.
Lieber MM
Urol Int; 1991; 47 Suppl 1():74-6. PubMed ID: 1949384
[TBL] [Abstract][Full Text] [Related]
27. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group.
van den Ouden D; Tribukait B; Blom JH; Fossa SD; Kurth KH; ten Kate FJ; Heiden T; Wang N; Schroder FH
J Urol; 1993 Aug; 150(2 Pt 1):400-6. PubMed ID: 8326563
[TBL] [Abstract][Full Text] [Related]
28. Use of fluorescent in situ hybridization for deoxyribonucleic acid ploidy analysis of prostatic adenocarcinoma.
Persons DL; Gibney DJ; Katzmann JA; Lieber MM; Farrow GM; Jenkins RB
J Urol; 1993 Jul; 150(1):120-5. PubMed ID: 8510232
[TBL] [Abstract][Full Text] [Related]
29. The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation.
Pollack A; Troncoso P; Zagars GK; von Eschenbach AC; Mak AC; Wu CS; Terry NH
Prostate; 1997 Apr; 31(1):21-8. PubMed ID: 9108882
[TBL] [Abstract][Full Text] [Related]
30. Flow cytometric nuclear DNA content analysis of renal tumors in children: prognostic significance of nuclear DNA ploidy.
Li P; Yokomori K; Tsuchida Y; Fujita M; Shimizu K; Tanaka E; Pianovski MA; Takemura T
Tumour Biol; 1995; 16(6):385-93. PubMed ID: 7569685
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of DNA ploidy in carcinoma of prostate.
Dejter SW; Cunningham RE; Noguchi PD; Jones RV; Moul JW; McLeod DG; Lynch JH
Urology; 1989 May; 33(5):361-6. PubMed ID: 2711553
[TBL] [Abstract][Full Text] [Related]
32. DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure.
Borre M; Høyer M; Nerstrøm B; Overgaard J
Prostate; 1998 Sep; 36(4):244-9. PubMed ID: 9719024
[TBL] [Abstract][Full Text] [Related]
33. DNA ploidy, Gleason score, pathological stage and serum PSA levels as predictors of disease-free survival in C-D1 prostatic cancer patients submitted to radical retropubic prostatectomy.
Di Silverio F; D'Eramo G; Buscarini M; Sciarra A; Casale P; Di Nicola S; Loreto A; Seccareccia F; De Vita R
Eur Urol; 1996; 30(3):316-21. PubMed ID: 8931963
[TBL] [Abstract][Full Text] [Related]
34. Flow cytometric DNA analysis of fresh prostatic resections. Correlation with conventional prognostic parameters in patients with prostate cancer.
Hussain MH; Powell I; Zaki N; Maciorowski Z; Sakr W; KuKuruga M; Visscher D; Haas GP; Pontes JE; Ensley JF
Cancer; 1993 Nov; 72(10):3012-9. PubMed ID: 7693326
[TBL] [Abstract][Full Text] [Related]
35. The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer.
Häggarth L; Auer G; Busch C; Norberg M; Häggman M; Egevad L
Scand J Urol Nephrol; 2005; 39(5):387-92. PubMed ID: 16257840
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of p53 and DNA ploidy following radical prostatectomy.
Deliveliotis C; Skolarikos A; Karayannis A; Tzelepis V; Trakas N; Alargof E; Protogerou V
World J Urol; 2003 Aug; 21(3):171-6. PubMed ID: 12844233
[TBL] [Abstract][Full Text] [Related]
37. Flow cytometric DNA analysis of stage D2 prostatic carcinoma.
Yokogi H; Mizutani M; Ishibe T
Urol Int; 1991; 47(2):57-9. PubMed ID: 1792707
[TBL] [Abstract][Full Text] [Related]
38. DNA heterogeneity in prostatic adenocarcinoma. A DNA flow cytometric mapping study with whole organ sections of prostate.
O'Malley FP; Grignon DJ; Keeney M; Kerkvliet N; McLean C
Cancer; 1993 May; 71(9):2797-802. PubMed ID: 8467459
[TBL] [Abstract][Full Text] [Related]
39. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy.
Gauwitz MD; Pollack A; el-Naggar AK; Terry NH; von Eschenbach AC; Zagars GK
Int J Radiat Oncol Biol Phys; 1994 Mar; 28(4):821-8. PubMed ID: 8138434
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
